{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:20Z","timestamp":1787010200239,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shaanxi Provincial Natural Science Basic Research Project","award":["2021JM-553"],"award-info":[{"award-number":["2021JM-553"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,16]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Delayed-release budesonide, as a novel oral agent, may be an effective treatment for IgA nephropathy. Its efficacy and safety in adult IgA nephropathy patients with estimated glomerular filtration rate (eGFR)\u2005&gt;\u200535\u2005mL\/min\/1.73\u2005m\u00b2 has been previously confirmed in the phase III clinical study (NeflgArd). For patients at high risk of progression to end-stage renal disease, it is uncertain whether delayed-release budesonide combined with cyclophosphamide on the basis of supportive therapy could improve the prognosis of adult IgA nephropathy patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 37-year-old male presented with fever (max 38.2\u00b0C) and sore throat, urinalysis revealed abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>\n                      Laboratory tests showed urinary protein of 2.98\u2005g\/d, serum creatinine of 321\u2005\u03bcmol\/L, eGFR of 20.27\u2005mL\/min\/1.73\u2005m\n                      <jats:sup>2<\/jats:sup>\n                      , plasma albumin 34.6\u2005g\/L. Renal biopsy pathology showed sclerosing IgA nephropathy (Lee grade \u2163, Oxford classification M0E0S1T1C0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient was treated with delayed-release budesonide (16\u2005mg\/d) for 36 weeks, in combination with intravenous cyclophosphamide (0.8\u2009g monthly for 6 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>\n                      After 36 weeks of therapy, the eGFR increased from 20.27 to 48.12\u2005mL\/min\/1.73\u2005m\n                      <jats:sup>2<\/jats:sup>\n                      , serum creatinine decreased from 321 to 157\u2005\u03bcmol\/L, urinary protein decreased from 2.98 to 0.378\u2005g\/d, and plasma albumin increased from 34.6 to 45.6\u2005g\/L. During the course of treatment, no significant drug-related adverse reactions were observed, except for a mild cold.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>\n                      This case suggests that delayed-release budesonide in combination with cyclophosphamide on the basis of supportive therapy is effective in treating adult IgA nephropathy patient with eGFR\u2005&lt;\u200530\u2005mL\/min\/1.73\u2005m\n                      <jats:sup>2<\/jats:sup>\n                      . This approach warrants further investigation in larger prospective studies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047060","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:01:41Z","timestamp":1768849301000},"page":"e47060","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Delayed-release budesonide combined with cyclophosphamide in a patient with IgA nephropathy with eGFR\u2005&lt;\u200530\u2005mL\/min\/1.73\u2005m\u00b2: A case report"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-5090","authenticated-orcid":false,"given":"Zhuan'e","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Nephrology, Shaanxi Provincial People\u2019s Hospital, Xi\u2019an, Shaanxi, China"},{"name":"Department of Nephrology, Shaanxi Second Provincial People\u2019s Hospital, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shaanxi Second Provincial People\u2019s Hospital, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinjuan","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shaanxi Second Provincial People\u2019s Hospital, Xi\u2019an, Shaanxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-8511","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shaanxi Provincial People\u2019s Hospital, Xi\u2019an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260119","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"R2-20260119","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases.","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"R3-20260119","doi-asserted-by":"crossref","first-page":"sfae230","DOI":"10.1093\/ckj\/sfae230","article-title":"Long-term outcomes of patients with IgA nephropathy in the German CKD cohort.","volume":"17","author":"Stamellou","year":"2024","journal-title":"Clin Kidney J"},{"key":"R4-20260119","doi-asserted-by":"crossref","first-page":"946165","DOI":"10.3389\/fphar.2022.946165","article-title":"Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease: a retrospective cohort study.","volume":"13","author":"Jia","year":"2022","journal-title":"Front Pharmacol"},{"key":"R5-20260119","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40620-020-00752-x","article-title":"Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.","volume":"33","author":"Ma","year":"2020","journal-title":"J Nephrol"},{"key":"R6-20260119","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.semnephrol.2018.05.016","article-title":"Aberrant glycosylation of the IgA1 molecule in IgA nephropathy.","volume":"38","author":"Novak","year":"2018","journal-title":"Semin Nephrol"},{"key":"R7-20260119","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Trgeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"R10-20260119","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA nephropathy: an interesting autoimmune kidney disease.","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am J Med Sci"},{"key":"R11-20260119","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","article-title":"Current treatment of IgA nephropathy.","volume":"43","author":"Floege","year":"2021","journal-title":"Semin Immunopathol"},{"key":"R12-20260119","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"R13-20260119","doi-asserted-by":"crossref","first-page":"506","DOI":"10.34067\/KID.0006702021","article-title":"Effect of cyclophosphamide and glucocorticoid therapy in IgA nephropathy: a single-center retrospective analysis.","volume":"3","author":"Beck","year":"2022","journal-title":"Kidney360"},{"key":"R14-20260119","doi-asserted-by":"crossref","first-page":"c131","DOI":"10.1159\/000070232","article-title":"Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.","volume":"93","author":"Rasche","year":"2003","journal-title":"Nephron Clin Pract"},{"key":"R15-20260119","doi-asserted-by":"crossref","first-page":"1093442","DOI":"10.3389\/fphar.2023.1093442","article-title":"Efficacy and safety of sequential immunosuppressive treatment for severe IgA nephropathy: a retrospective study.","volume":"14","author":"Luo","year":"2023","journal-title":"Front Pharmacol"},{"key":"R16-20260119","doi-asserted-by":"crossref","first-page":"1175088","DOI":"10.3389\/fneph.2023.1175088","article-title":"IgA nephropathy: a review of existing and emerging therapies.","volume":"3","author":"Noor","year":"2023","journal-title":"Front Nephrol"},{"key":"R17-20260119","doi-asserted-by":"crossref","first-page":"e21000","DOI":"10.1097\/MD.0000000000021000","article-title":"Budesonide versus systemic corticosteroids in IgA nephropathy: a retrospective, propensity-matched comparison.","volume":"99","author":"Ismail","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R18-20260119","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.1038\/s41598-023-47393-1","article-title":"An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression.","volume":"13","author":"Obri\u0219c\u0103","year":"2023","journal-title":"Sci Rep"},{"key":"R19-20260119","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7150\/thno.104631","article-title":"The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"R20-20260119","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.1038\/s41467-022-34456-6","article-title":"Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits.","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"R21-20260119","doi-asserted-by":"crossref","first-page":"23247096241260964","DOI":"10.1177\/23247096241260964","article-title":"Delayed-release budesonide in a patient with progressive IgA nephropathy and stage 4 chronic kidney disease: a case report.","volume":"12","author":"Gholizadeh Ghozloujeh","year":"2024","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R22-20260119","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:01:44Z","timestamp":1768849304000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047060","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"2025-08-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}